Neurol. praxi. 2012;13(4):183-187

Myotonic dystrophies

MUDr.Radim Mazanec, Ph.D.1, Mgr.Zuzana Mušová, Ph.D.2
1 Neurologická klinika 2. LF UK a FN v Motole, Praha
2 Ústav biologie a lékařské genetiky 2. LF UK a FN v Motole, Praha

The myotonic dystrophies (DM) are primary, progressive and degenerative disorders of skeletal muscles. Besides involvement of skeletal

muscles, they cause heart, eyes, endocrine and brain disorders. DM are the most common muscular dystrophies in adults, they cause life

shortening and affect quality of life. Main clinical features are myotonia and progressive muscle weakness.The classification distinguishes

two main types of DM –myotonic dystrophy type 1 (Steinert´s disease), myotonic dystrophy type 2 (proximal myotonic myopathy, PROMM).

A special type of DM1 is congenital myotonic dystrophy. The molecular genetics procedures are the most important diagnostic tools to

establish the correct diagnosis. The molecular basis of myotonic dystrophies is expansion of an unstable trinucleotide repeat sequence CTG

in noncoding part of a DMPK1 gene in DM1 and tetranucleotide repeat sequence CCTG of ZNF9 gene in DM2. Further, electromyography is

an important diagnostic procedure to confirm specific myotonic discharges in skeletal muscles. The causative treatment is not available,

but long term cardiological and ophtalmological care is required. The genetic counseling is very important in DM1 and DM2 families.

Keywords: myotonia, muscular dystrophies, myotonic dystrophy, molecular genetics

Published: July 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mazanec R, Mušová Z. Myotonic dystrophies. Neurol. praxi. 2012;13(4):183-187.
Download citation

References

  1. Amato AA, Russell JA. Myotonic Dystrophies. In: Neuromuscular Disorders. Amato AA, Russell JA. McGrawHill Medical; 2007: 647-653.
  2. Ambler Z. Myotonická dystrofie. Neurol. praxi 2004; 3: 142-145.
  3. Argov Z, de Visser M. What we do not know about pregnancy in hereditary neuromuscular disorders. Neuromuscul Disord. 2009; 19(10): 675-679. Go to original source... Go to PubMed...
  4. Bártková A. Poruchy srdečního rytmu ve vztahu k neurologickým chorobám. Neurol. praxi 2005; 1: 8-11.
  5. Bassez G, Lazarus A, Desguerre I, Varin J, Laforet P, Becane HM, Meune C, Arne-Bes MC, Ounnoughene Z, Radvanyi H, Eymard B, Duboc D. Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurology. 2004; 63: 1939. Go to original source... Go to PubMed...
  6. Bennun M, Goldstein B, Finkelstein Y, Jedeikin R. Continuous propofol anestesia for patients with myotonic dystrophy. Br J Anaesth 2000; 85: 407-409. Go to original source... Go to PubMed...
  7. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H. Molecular basisof myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3´ end of a transript encoding a protein kinase family member. Cell 1992; 68: 799-808. Go to original source... Go to PubMed...
  8. Bungener C, Jouvent R, Delaporte C. Psychopathological and emotional deficits in myotonic dystrophy. J Neurol Neurosurg Psych 1998; 65: 353-356. Go to original source... Go to PubMed...
  9. Day JW, Ricker K, Jacobsen JF, Rassmussen LJ, Dick KA, Kress W. Myotonic dystrophy type 2. Molecular, diagnostic and clinical spectrum. Neurology; 60(4): 657-664. Go to PubMed...
  10. Emery AEH. Population frequencies of inherited neuromuscular diseases - a world survey. Neuromuscul Disord 1991; 1: 19-29. Go to original source... Go to PubMed...
  11. Foff PE, Mahadevan MS. Therapeutics development in myotonic dystrophy type 1. Muscle Nerve 2011; 44: 160-169. Go to original source... Go to PubMed...
  12. Gregoratos G, Abrams J, Epstein AE. ACA/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhytmia devices. Circulation 2002; 106: 2145-2161. Go to original source... Go to PubMed...
  13. Harper P. Myotonic Dystrophy, vol. 37, 3rd ed., Major Probléme in Neurology 37; Saunders-Elsevier 2001: 320.
  14. Kakourou G, Dhanjal S, Mamas T, Gotts S, Doshi A, Fordham K, Serhal P, Ranieri DM, Delhanty JD, Harper JC, SenGupta SB. Preimplantation genetic diagnosis for myotonic dystrophy type 1 in the UK. Neuromuscul Disord. 2008; 18(2): 131-136. Go to original source... Go to PubMed...
  15. Kraus J. Myotonická dystrofie (Curschmann-Batten-Steinert). Neurol. praxi 2002; 4: 183-186.
  16. Liquori CL, Ricker K, Moseley ML, Jacobsen JF Kress W, Naylor SL. Myotonic dystrophy type 2 caused bya CCTG expansion in intron 1 of ZNF9. Science 2001; 293: 864-867. Go to original source... Go to PubMed...
  17. Machuca-Tzili L, Brook D, Hilton-Jones D. Clinical and molecular aspect of the myotonic dystrophies: a review. Muscle Nerve 2005; 32: 1-18. Go to original source... Go to PubMed...
  18. Minnerop M, Weber B, Schoene-Backe JC, Roeske S, Mirbach S. The brain in myotonic dystrophy 1+2: evidence for predominant white matter disease. Brain 2011; 134: 3530-3546. Go to original source... Go to PubMed...
  19. Motta J, Guilleminault C, Billingham M, Barry W, Mason J. Cardiac abnormalities in myotonic dystrophy: Electrophysiologic and histologic studies. Am J Med 1979; 67: 467-473. Go to original source... Go to PubMed...
  20. Moxley RT, Meola G. The Myotonic Dystrophies. In: The Molecular and Genetic Basis of Neurologic and Psychiatric Disease. Rosenberg RN, DiMauro S, Paulson HL, Ptacek L, Nestler EJ, eds. Philadelphia: Wolters Kluwer; 2008: 532-541.
  21. Portwood MM, Wicks JJ, Lieberman JS, Fowler JM Jr. Intellectual and cognitive function in adults with myotonic muscular dystrophy. Arch Phys Med Rehabil 1986; 67(5): 299-303.
  22. Ranum LP, Cooper TA. RNA-mediated neuromuscular disorders. Annu Rev Neurosci 2006; 29: 259-277. Go to original source... Go to PubMed...
  23. Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet 2004; 74: 793-804. Go to original source... Go to PubMed...
  24. Sovari AA, Bodine CK, Farokhi F. Cardiovascular manifestations of myotonic dystrophy-1. Cardiol Rev. 2007; 15(4): 191-194. Go to original source... Go to PubMed...
  25. Suokas KI, Haanpää M, Kautiainen H, Udd B, Hietaharju AJ. Pain in patients with myotonic dystrophy type 2: a postal survey in Finland. Muscle Nerve 2012; 45: 70-74. Go to original source... Go to PubMed...
  26. Talbot K, Stradling J, Crosby J, Hilton-Jones D. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy.Neuromuscul Disord 2003; 13: 357-364. Go to original source... Go to PubMed...
  27. Thornton C. The Myotonic Dystrophies. In: Structural and Molecular Basis of Skeletal Muscle Diseases, eds. Karpati G. ISN Neuropath Press, Basel, 2002: 108-114.
  28. Thorton CA, Griggs RC, Moxley RT III. Myotonic dystrophy with no trinucleotide repeat expansion.Ann Neurol 1994; 35: 269-272. Go to original source... Go to PubMed...
  29. Vihola A, Bassez G, Meola G, Zhang S, Haapasalo H, Paetau A. Histopathological differences of myotonic dystrophy type1 (DM1) and PROMM/DM2. Neurology 2003; 60: 1854-1857. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.